These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24476765)

  • 1. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
    Ray A; Tian Z; Das DS; Coffman RL; Richardson P; Chauhan D; Anderson KC
    Leukemia; 2014 Aug; 28(8):1716-24. PubMed ID: 24476765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
    Chauhan D; Singh AV; Brahmandam M; Carrasco R; Bandi M; Hideshima T; Bianchi G; Podar K; Tai YT; Mitsiades C; Raje N; Jaye DL; Kumar SK; Richardson P; Munshi N; Anderson KC
    Cancer Cell; 2009 Oct; 16(4):309-23. PubMed ID: 19800576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.
    Ray A; Das DS; Song Y; Macri V; Richardson P; Brooks CL; Chauhan D; Anderson KC
    Leukemia; 2017 Dec; 31(12):2652-2660. PubMed ID: 28479592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Chauhan D; Tian Z; Nicholson B; Kumar KG; Zhou B; Carrasco R; McDermott JL; Leach CA; Fulcinniti M; Kodrasov MP; Weinstock J; Kingsbury WD; Hideshima T; Shah PK; Minvielle S; Altun M; Kessler BM; Orlowski R; Richardson P; Munshi N; Anderson KC
    Cancer Cell; 2012 Sep; 22(3):345-58. PubMed ID: 22975377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
    Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
    Schmidt-Hieber M; Dabrowski R; Weimann A; Aicher B; Lohneis P; Busse A; Thiel E; Blau IW
    Invest New Drugs; 2012 Apr; 30(2):480-9. PubMed ID: 21080211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
    Cagnetta A; Cea M; Calimeri T; Acharya C; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Zhong MY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2013 Aug; 122(7):1243-55. PubMed ID: 23823317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
    Abdi J; Mutis T; Garssen J; Redegeld FA
    PLoS One; 2014; 9(5):e96608. PubMed ID: 24794258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
    De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
    Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
    Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
    Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
    Görgün GT; Whitehill G; Anderson JL; Hideshima T; Maguire C; Laubach J; Raje N; Munshi NC; Richardson PG; Anderson KC
    Blood; 2013 Apr; 121(15):2975-87. PubMed ID: 23321256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.
    Ray A; Song Y; Du T; Chauhan D; Anderson KC
    Oncogene; 2020 Mar; 39(13):2786-2796. PubMed ID: 32024967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
    Mirandola L; Yu Y; Chui K; Jenkins MR; Cobos E; John CM; Chiriva-Internati M
    PLoS One; 2011; 6(7):e21811. PubMed ID: 21765917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
    Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
    Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J; Koyama D; Mukai HY; Furukawa Y
    Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.